Drug delivery to the brain is hindered by the presence of the blood–brain barrier (BBB).
Although the BBB restricts the passage of many substances, it is actually selectively …

Peptides and recombinant proteins such as neurotrophins, enzymes and monoclonal
antibodies, have not been developed as new drugs for the brain because these large …

Background and Purpose—We tested the hypothesis that there are significant long-term
local vascular changes after ministroke that could form a basis for functional recovery …

Biologics are potential new therapeutics for many diseases of the central nervous system.
Biologics include recombinant lysosomal enzymes, neurotrophins, decoy receptors, and …

Owing to its high disability and mortality rates, stroke has been the second leading cause of
death worldwide. Since the pathological mechanisms of stroke are not fully understood …

Astrocytes, which are homeostatic cells of the central nervous system (CNS), display
remarkable heterogeneity in their morphology and function. Besides their physical and …

The neuroprotective action of brain-derived neurotrophic factor (BDNF) was evaluated in a
rat model of transient forebrain ischemia. A continuous intraventricular infusion of BDNF for …

Considerable progress has been made recently in understanding the molecular
mechanisms of angiogenesis, which like most other biological processes is the result of …

Although regeneration of injured neurons does not occur after trauma in the central nervous
system (CNS), there is often significant recovery of functional capacity with time. Little is …

Abstract Perinatal hypoxic‐ischemic (HI)‐related brain injury is an important cause of
morbidity and long‐standing disability in newborns. The only currently approved therapeutic …